![]() |
|
|
Vol. 288, Issue 1, 133-138, January 1999
Department of Pharmacology, College of Medicine, Pusan National University, Pusan, Korea (C.D.K., H.H.K., K.W.A.); and Center for Biofunctional Molecules, Pohang University of Science and Technology, Pohang, Korea (K.W.H.)
| |
Abstract |
|---|
|
|
|---|
We investigated the mechanism or mechanisms by which rebamipide
protects against the gastric mucosal inflammation associated with
Helicobacter pylori. The production of interleukin
(IL)-8 in association with expression of IL-8 mRNA was greatly
increased in the H. pylori-infected Kato III cells in a
concentration- and time-dependent manner, whereas the secretion of IL-6
and tumor necrosis factor-
was not detectable. The increased
production of IL-8 and expression of IL-8 mRNA were significantly
inhibited by rebamipide (100-1000 µM) in a concentration-dependent
manner. Formyl-methionyl-leucyl-phenylalanine (1 nM), as well as
conditioned medium (CM) that was produced from H.
pylori-infected Kato III cells, caused an increase in surface
expression of CD11b on human neutrophils and an increase in neutrophil
adhesion to the human umbilical vein endothelial cells. Rebamipide also
suppressed the adherence of neutrophils to endothelial cells as well as
the expression of CD11b on neutrophils induced by
formyl-methionyl-leucyl-phenylalanine and CM. Furthermore, CM-induced
neutrophil adhesion to the endothelial cells was significantly
inhibited by IL-8-neutralizing antibody, suggesting that IL-8 is
implicated in the CM-induced neutrophil adhesion to the cultured human
umbilical vein endothelial cells. It is concluded that rebamipide
exerts its preventive effect against H. pylori-evoked
gastric mucosal cell inflammation by inhibition of the neutrophil
adherence to the endothelial cells as well as by suppressing the
surface expression of CD11b on neutrophils and the production of
proinflammatory cytokine such as IL-8 from gastric epithelial cells.
| |
Introduction |
|---|
|
|
|---|
Several
studies have suggested that neutrophils are the chief provocative cells
in the development of inflammation and injury in a variety of tissues,
including the gastric mucosa (Ninemann, 1988
). Despite increasing
evidence of a major role for neutrophils in the tissue injury, the
mechanism or mechanisms underlying activation and recruitment of these
cells into the tissue are not clear. Recent studies have demonstrated
that cultured human gastric epithelial cells are capable of expressing
and releasing several proinflammatory cytokines, including IL-8, that
directly or indirectly influence the activity of neutrophils.
It is known that Helicobacter pylori bacteria are closely
associated with gastric and duodenal ulcer diseases (Graham, 1991
; Cover and Blaser, 1992
; Megraud and Lamouliatte, 1992
). Yoshida et al.
(1993)
and Evans et al. (1995)
have reported that the products of
H. pylori elicit gastrointestinal inflammation by promoting neutrophil adhesion to endothelial cells via CD11b/CD18-dependent interactions with ICAM-1 on endothelium. Furthermore, H. pylori intimately adheres to the surface of gastric epithelium
(Hessey et al., 1990
) and stimulates production of chemoattractants
from the epithelial cells (Crabtree et al., 1994
; Crowe et al., 1995
). In line with these facts, IL-8 activity was also demonstrated in
relation with histological severity in H. pylori-associated antral gastritis (Ando et al., 1996
; Crabtree, 1996
).
Rebamipide
(2-(4-chlorobenzoylamino)-3-[2-(1H)-quinolinon-4-yl]propionic acid)
has been reported to exert a preventive effect on the drug-induced
gastric ulcer formation by inhibiting neutrophil activation (Ogino et
al., 1992
) and lipid peroxidation (Yoshikawa et al., 1993
). Recently,
we have reported that rebamipide prevents gastric lesions induced by
ischemia-reperfusion via inhibition of the production of reactive
oxygen species from activated neutrophils (Kim and Hong, 1995
). More
recently, we found that the inhibitory effect of rebamipide on the
neutrophil-mediated gastric mucosal cell injury was ascribed to the
alterations in the neutrophil membranes, that is, a decrease in the
number of binding sites for fMLP to its receptors (Kim and Hong, 1997
).
However, the mechanism or mechanisms by which rebamipide exerts its
cytoprotective effect against gastric cell damage are not yet fully determined.
In the present study, our goal was to investigate the underlying mechanism or mechanisms of the cytoprotective action of rebamipide against H. pylori-infected gastric mucosal cell damage. Thus, we measured the effects of rebamipide on (1) the production of IL-8 and expression of IL-8 mRNA in the Kato III cells in response to H. pylori, (2) the surface expression of CD11b on human neutrophils activated by either fMLP and CM, and (3) the fMLP- and CM-stimulated neutrophil adherence to the HUVECs in comparison with the effects of IL-8-neutralizing antibody.
| |
Materials and Methods |
|---|
|
|
|---|
Culture of Gastric Epithelial Cell Line. Kato III cells (gastric carcinoma; ATCC HTB 103) as human cell line was purchased from the American Type Culture Collection (Rockville, MD). Cells were grown in a RPMI 1640 medium supplemented with 10% fetal calf serum, 100 U/ml penicillin, and 100 µg/ml streptomycin. Cells were seeded onto 24-well tissue culture plates at a density of 2 × 105 cells per well and cultured for 3 days. Before H. pylori stimulation, each well was washed three times with 1 ml of fresh antibiotic-free culture medium. The number of epithelial cells seeded and days of growth required to achieve this final number of cells were kept constant so that any effect of cell growth would contribute minimally to any changes in cytokine production.
Culture of Endothelial Cells. HUVECs (ATCC HB-11608) were cultured in Medium 199 (GIBCO, Grand Island, NY) supplemented with 10% heat-inactivated fetal calf serum, heparin sodium (90 µg/ml), antibiotics (100 U/ml penicillin and 100 µg/ml streptomycin), and endothelial cell growth supplement (150 µg/ml; Sigma Chemical, St. Louis, MO). Cells were grown to confluence at 37°C on 0.5% gelatin-coated 24-well cell culture plates and used for experiments at no greater than passage 8.
Culture of H. pylori. H. pylori (ATCC 43526) was inoculated on a chocolate agar plate and incubated for 72 h in a microaerobic and humidified atmosphere at 37°C. Whole H. pylori was harvested from a culture plate with sterile cotton swabs, resuspended in the antibiotic-free RPMI 1640 medium (109 bacteria/ml), and added to the cultured Kato III cell medium at various bacteria-to-Kato III cell ratios (1:1, 10:1, and 100:1). For collection of CM, Kato III cells were cocultured with H. pylori for 24 h at a bacteria-to-Kato III cell ratio of 100:1. To remove H. pylori from the CM, CM obtained was centrifuged at 1400g for 20 min, and the supernatant was passed through a 0.2-µm syringe-adapted filter.
Cytokine Assay.
The levels of IL-6, IL-8, and TNF-
in the
culture supernatants were assayed with the ELISA kits (R and D Systems,
Minneapolis, MN). The supernatant (50 µl) and buffer standard
solution were dispersed into microtitration wells coated with the
polyclonal antibody specific for IL-6, IL-8, and TNF-
, respectively.
After a 2-h incubation period at room temperature, the wells were
washed, and 100 µl of the peroxidase-conjugated secondary antibody
was added. After a 2-h incubation at room temperature, the wells were washed, and 100 µl of peroxidase substrate was added to each well, after which the absorbance at 450 nm was measured.
RT-PCR Amplification for IL-8 mRNA. IL-8 mRNA gene expression was assessed using RT-PCR standardized by coamplifying IL-8 with the housekeeping gene GAPDH, which served as an internal control because it must control for variations due to sample preparation. Cellular RNA was extracted from the Kato III cells infected in vitro with H. pylori. RNA (2 µg) was reverse-transcribed into cDNA at 42°C for 1 h. Then, the cDNA (25 µl) was amplified with the commercially available PCR primers (ClonTech Laboratories, Palo Alto, CA) for IL-8 or GAPDH in a 50-µl reaction mixture, which contained Taq polymerase for 30 cycles of 45 s at 94°C, 45 s at 60°C, and 2 min at 72°C in a DNA thermal cycler (Perkin-Elmer Cetus, Norwalk, CO). As a negative control for PCR amplification, the cDNA sample was omitted from the reaction mixture. The amplified products were subjected to electrophoresis in a 1.8% agarose gel containing ethidium bromide and were visualized by UV transillumination. Results were normalized based on the levels of GAPDH expression.
Immunofluorescence Flow Cytometry. Surface expression of CD11b on the neutrophils was determined by immunofluorescence flow cytometry. Briefly, 106 neutrophils purified from human peripheral blood were incubated with either fMLP or CM for 30 min at 37°C. Rebamipide was added 15 min before stimulation with fMLP or CM. Subsequently, the neutrophils were washed with PBS, treated with 10 µl of the phycoerythrin-conjugated monoclonal antibody against CD11b (clone D12; Becton Dickinson), and then incubated for 60 min in the dark at 4°C. Thereafter, the cells were washed with PBS containing 0.1% azide, fixed with 0.5 ml of 1% paraformaldehyde, and then analyzed using FACS Vantage (Becton Dickinson). The data were expressed as percentages of total fluorescent intensity (TFI) of the surface antigen expression. TFI was calculated as TFI = % positive events × mean channel of fluorescence.
Isolation of Neutrophils. Human neutrophils were isolated from 0.2% EDTA-anticoagulated whole blood collected by venipuncture from normal donors. Neutrophils were obtained using standard dextran sedimentation and gradient separation on Histopaque 1077 (Sigma Chemical). This procedure yields a polymorphonuclear leukocyte population that is 95% to 98% viable (trypan blue exclusion) and 98% pure (acetic acid-crystal violet staining).
Neutrophil Adhesion Assay. Isolated neutrophils were suspended in PBS and radiolabeled by incubation of the neutrophils (2 × 107 cells/ml) with 30 µCi of Na51CrO4/ml at 37°C for 60 min. The cells were washed twice with cold PBS at 250g for 8 min to remove unincorporated radioactivity and then resuspended in plasma-free PBS. Radiolabeled neutrophils were added to HUVEC monolayers at a neutrophil-to-endothelial cell ratio of 10:1 with or without stimulants (1 nM fMLP or CM). After incubation at 37°C for 30 min in the presence or absence of rebamipide (100-1000 µM) or IL-8-neutralizing antibody (1, 3, and 10 µg/ml), the supernatant was removed; then, the endothelial monolayers were washed, and the remaining cells were lysed. The 51Cr activities of the supernatant, wash fluid, and lysate were assessed in a gamma counter (Wallac 1470 Wizard). The percentage of added neutrophils that adhered to the HUVEC monolayers was determined as follows:
|
|
Drugs. Rebamipide (Otsuka Pharmaceutical, Tokushima, Japan) was dissolved in 10 mM NaOH solution at a concentration of 10 mM. fMLP and anti-human IgG (Fab specific) were purchased from Sigma Chemical. Anti-human IL-8 (purified mouse monoclonal IgG1 was obtained from R and D Systems.
Statistics. All data are expressed as mean ± S.E.M. Statistical differences between groups were determined by Student's t test. Differences were significant when P < .05.
| |
Results |
|---|
|
|
|---|
Cytokine Production by H. pylori-Stimulated Kato III
Cells.
Analysis of the cytokine production in the culture medium
demonstrated that Kato III cells constitutively released 9.2 ± 2.2 ng/106 cells of IL-8, whereas IL-6 and TNF-
were not
detectable. After exposure to H. pylori, the secretion
of IL-8, but not IL-6 and TNF-
, from Kato III cells was markedly
increased with increased number of bacteria. In the preliminary
experiment, IL-8 was not detectable in the culture media of H.
pylori alone (Fig. 1).
Secretion of IL-8 from Kato III cells largely increased with increased
number of bacteria, up to 400%, at ratios of 10 and 100 H.
pylori:1 Kato III cell (P < .05 and
P < .01, respectively). Therefore, in this experiment, a ratio of 100 bacteria:1 Kato III cell was routinely applied.
|
|
|
PCR Analysis of IL-8 mRNA Expression in Kato III Cells. The potential of H. pylori to stimulate IL-8 synthesis from Kato III cells was studied by RT-PCR analysis. Figure 4 shows a representative RT-PCR analysis of IL-8 and GAPDH mRNA. Consistent with the secretion of IL-8, which was exhibited in the culture media, analysis of the mRNA expression demonstrated that Kato III cells had a very low level of IL-8 mRNA expression in H. pylori-free state (Fig. 4a). The IL-8/GAPDH mRNA ratios markedly increased in the H. pylori-infected cells in a concentration-dependent manner from 106 to 109 H. pylori/106 Kato III cells (Fig. 4, a and b). The level of IL-8 mRNA also increased with increased infection time from 3 to 24 h (data not shown). The increase in IL-8 mRNA expression in the H. pylori-infected Kato III cells was significantly suppressed by rebamipide (300 and 1000 µM; P < .05, respectively) in a concentration-dependent manner (Fig. 5, a and b).
|
|
Expression of CD11b on Neutrophils. Under stimulation with fMLP (1 nM), CM, and fMLP plus CM, neutrophils showed a large increase in the surface expression of CD11b on their membranes. The ability of fMLP plus CM to induce CD11b expression was comparatively larger than that of fMLP or CM alone (Fig. 6, inset). The increased expression of CD11b stimulated by either fMLP or CM was significantly suppressed by pretreatment with rebamipide (300 and 1000 µM) in a concentration-dependent manner. However, the basal expression of CD11b on neutrophils, unless stimulated, was not affected by rebamipide (Fig. 6).
|
Neutrophil Adherence to Endothelial Cells. The percentage of total neutrophils adhering to the cultured HUVECs was significantly increased in the presence of fMLP (1 nM) and CM. Increased neutrophil adhesion stimulated by either fMLP or CM was significantly suppressed by rebamipide (300 and 1000 µM) in a concentration-dependent manner (Fig. 7). The viability of neutrophils and HUVECs was not affected by the addition of 1000 µM rebamipide to the medium.
|
Effect of IL-8-Neutralizing Antibody on Neutrophil Adhesion. As shown in Fig. 8, CM significantly enhanced the percentage of neutrophil adherence to the cultured HUVECs, which was concentration-dependently suppressed by IL-8-neutralizing antibody as it was by rebamipide, whereas anti-human IgG exerted little effect, thereby suggesting that IL-8 secretion from gastric epithelial cells may be implicated in the CM-induced neutrophil adhesion to the endothelium.
|
| |
Discussion |
|---|
|
|
|---|
A number of experiments indicate that infection with H. pylori is characterized by elevation of mucosal inflammatory
cytokines such as IL-6, IL-8, and TNF-
(Crabtree et al., 1994
;
Gionchetti et al., 1994
; Noach et al., 1994
) in association with
neutrophil-mediated tissue injury (Wallace, 1990
; Blaser, 1992
).
In the present study, rebamipide significantly inhibited (1) the
H. pylori-evoked production of IL-8 and expression of IL-8
mRNA in the Kato III cells, (2) the surface expression of CD11b on
neutrophils stimulated by either fMLP or CM, and (3) the fMLP- or
CM-stimulated neutrophil adherence to the HUVECs.
It has been reported that rebamipide has an oxygen radical-scavenging
effects (Yoshikawa et al., 1993
), and it prevents gastric ulcers
induced by ethanol and diethyldithiocarbamate, which appear to be the
conditions that increase oxidative stress in the organs (Takeuchi et
al., 1996
). Clinically, rebamipide has been tried with some efficacy
against the patients with gastritis and/or gastric ulcer infected by
H. pylori (Davies et al., 1994
). IL-8 is secreted by several
cell types, including monocytes, endothelial cells, and gastric
epithelial cells (Baggiolini et al., 1989
; Yasumoto et al., 1992
), and
plays a role for potent inflammatory mediator by activating neutrophils
(Huber et al., 1991
). Our present study showed that IL-8 production was
significantly increased in the culture medium of H. pylori-infected Kato III cells in a H. pylori
density-dependent manner, but those of IL-6 and TNF-
were not
detectable. These results were consistent with the report of Huang et
al. (1995)
. They conducted the RT-PCR analysis of the synthesis of
IL-6, IL-8, and TNF-
in Kato III cells in response to H. pylori (CCUG 17874), and they found no expression of mRNA for IL-6
and TNF-
, whereas mRNA for IL-8 was highly expressed in response to
H. pylori. The results suggest that IL-8 generated by Kato
III cells may be closely related with the gastritis caused by H. pylori infection.
In further study, the increases in IL-8 production and expression of IL-8 mRNA in Kato III cells were significantly inhibited by rebamipide, suggesting that rebamipide may suppress the synthesis of IL-8 in the H. pylori-infected gastric mucosal cells. These results provide the evidence that rebamipide can protect gastric mucosal cells from damage induced by H. pylori infection through inhibition of production of IL-8 from gastric mucosal cells.
On the other hand, the CD11b/CD18 glycoprotein complex expressed on
neutrophils is known as one of the important mediators of neutrophil
adhesion to endothelial cells in inflammation (House and Lipowsky,
1987
; Diamond et al., 1990
; Yoshida et al., 1993
). CD11b/CD18
glycoprotein is stored within specialized granules of resting
neutrophils and, when activated, is translocated to the cell surface by
granule fusion (Bainton et al., 1987
). Neutrophil activation also
triggers functional activation of preexisting cell surface CD11b/CD18,
presumably through conformational or topological alterations (Buyon et
al., 1988
). In the present study, we used fMLP and CM for activation of
neutrophils. The latter was produced from H. pylori-infected
Kato III cells as a stimulant. CM as well as fMLP (1 nM) caused a large
increase in the surface expression of CD11b on the neutrophil
membranes, and the increased expressions of CD11b were significantly
suppressed by rebamipide (300 and 1000 µM) in a
concentration-dependent manner. These results suggest that rebamipide
possesses an ability to inhibit the neutrophil adhesion to endothelial
cells by inhibiting the surface expression of CD11b on neutrophils,
thereby suppressing the acute inflammation evoked by activated neutrophils.
Our results further demonstrated that not only fMLP but also CM largely
increased the neutrophil adhesion to HUVECs and that these adhesive
interactions were significantly suppressed by rebamipide. At present
time, it is not clear whether fMLP itself or an fMLP-related substance
in CM is implicated as a chemotactic factor in H. pylori-induced inflammation. In a study directed to explain the
mechanism by which H. pylori recruits inflammatory cells,
Mooney et al. (1991)
have shown that H. pylori synthesizes
and secretes fMLP as a chemotactic substance. Reportedly, stimulation
of neutrophils with chemotactic agents leads to increased expression of
CD11b/CD18 on neutrophils (House and Lipowsky, 1987
; Diamond et al.,
1990
). Yoshida et al. (1993)
also postulated that the hyperadhesive
response induced by the H. pylori extract was dependent on
CD11a/CD18 on neutrophils. We recently explored how rebamipide exerts
its inhibitory effect on fMLP-stimulated neutrophil functions such as
aggregation, release of myeloperoxidase, and superoxide anion
production (Kim and Hong, 1995
). These findings were ascribed to the
decreased binding of [3H]fMLP to its receptors
on neutrophils (Kim and Hong, 1997
). Interestingly, CM-induced increase
in neutrophil adhesion to the endothelial cells was significantly
inhibited by IL-8-neutralizing antibody, as it was by rebamipide. This
result strongly suggests that IL-8 secreted from gastric epithelial
cells infected by H. pylori may be implicated in the signal
transduction of the CM-induced neutrophil adhesion to the cultured HUVECs.
In summary, rebamipide exerts the preventive effects against H. pylori-infected gastric cell damage by inhibiting the production of epithelial cell-derived proinflammatory cytokines such as IL-8 and by suppressing the fMLP- or CM-induced surface expression of CD11b on neutrophils, thereby inhibiting adhesion and migration of neutrophils. Further investigation to identify the molecular mechanism or mechanisms involved in the suppression of IL-8 and CD11b expression by rebamipide may provide more valuable information for the therapeutic approaches to gastritis and gastric and duodenal ulcers in response to a variety of pathogens.
| |
Acknowledgments |
|---|
The authors thank Dr. Dai Hyun Yu for his critical review of the manuscript. The gift of rebamipide from Otsuka Pharmaceutical Co. Ltd. (Japan) is greatly acknowledged.
| |
Footnotes |
|---|
Accepted for publication August 6, 1998.
Received for publication May 22, 1998.
1 This study was supported by research funds from Korea Otsuka Pharmaceutical Co., Ltd., and the Center for Biofunctional Molecules at Pohang University of Science and Technology.
Send reprint requests to: Ki Whan Hong, M.D., Doctor of Philosophy Department of Pharmacology, College of Medicine, Pusan National University, Ami-Dong 1-Ga, Seo-Gu Pusan 602-739, Korea. E-mail: kwhong{at}hyowon.pusan.ac.kr
| |
Abbreviations |
|---|
IL, interleukin; fMLP, formyl-methionyl-leucyl-phenylalanine; HUVEC, human umbilical vein endothelial cell; CM, conditioned medium; RT, reverse transcription; PCR, polymerase chain reaction; TNF, tumor necrosis factor; PBS, phosphate-buffered saline.
| |
References |
|---|
|
|
|---|
, interleukin-1
, and interleukin-8 production in patients with Helicobacter pylori infection.
Scand J Gastroenterol
29:
425-429[Medline].
and interferon-
synergistically induce interleukin 8 production in a human gastric cancer cell line through acting concurrently on AP-1 and NF-
B-like binding sites of the interleukin 8 gene.
J Biol Chem
267:
22506-22511This article has been cited by other articles:
![]() |
W.-H. Sun, S. Tsuji, M. Tsujii, E. S. Gunawan, N. Kawai, A. Kimura, Y. Kakiuchi, M. Yasumaru, H. Iijima, Y. Okuda, et al. Induction of Cyclooxygenase-2 in Rat Gastric Mucosa by Rebamipide, a Mucoprotective Agent J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 447 - 452. [Abstract] [Full Text] |
||||
![]() |
C. D. Kim, Y. K. Kim, S. H. Lee, and K. W. Hong Rebamipide Inhibits Neutrophil Adhesion to Hypoxia/Reoxygenation-Stimulated Endothelial Cells via Nuclear Factor-kappa B-Dependent Pathway J. Pharmacol. Exp. Ther., September 1, 2000; 294(3): 864 - 869. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||